about
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsMetabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1Immunotherapy of systemic sclerosisNeoplastic disease after liver transplantation: Focus on de novo neoplasmsDo wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsSirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases.IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells.Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.The role of B cells in solid organ transplantation.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Flt3L combined with rapamycin promotes cardiac allograft tolerance by inducing regulatory dendritic cells and allograft autophagy in mice.Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case seriesRapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8(+) T cells in vitro and in vivo.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationIn remembrance of things past: memory T cells and transplant rejection.Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapyImmunosuppressant drug monitoring: is the laboratory meeting clinical expectations?Cytochrome P450 3A polymorphisms and immunosuppressive drugs.Clinical application of sirolimus in renal transplantation: an update.Sirolimus: its role in nephrology.Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cellsThe role and value of sirolimus administration in kidney and liver transplantation.Regulation of alloimmune Th1 responses by the cyclin-dependent kinase inhibitor p21 following transplantation.Antihypertensive agents and renal transplantation.Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.Nanomedicines in renal transplant rejection--focus on sirolimusUpdate on immunosuppressive drugs used in solid-organ transplantation and their nutrition implications.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor MiceMicrobial synthesized biodegradable PHBHHxPEG hybrid copolymer as an efficient intracellular delivery nanocarrier for kinase inhibitor.Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning.Layer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of rapamycin.PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.Renal association clinical practice guideline in post-operative care in the kidney transplant recipientSimultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS).Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival.A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
P2860
Q24246340-E6E58E20-31C3-4A28-A3B2-E81A21636E5AQ24313010-691BC27E-77E5-4DB7-AD5B-0F88247BFBC4Q24634395-D37757DE-577E-485C-9C1A-3F62610E0971Q26798306-BFD7D710-2200-4B71-9D2A-0580DE721813Q26823281-7B5D13F3-021C-4BE8-BFC1-56A98460E6CCQ33368841-B0F45BC6-EDAD-4788-8D8E-35C0D8A6525CQ33551489-97C9656A-A794-4CA7-8AA6-51D09B5F665CQ33737181-3A6CF072-15A7-497B-AAF9-3C137D3773E1Q33891696-A274CA08-BD51-4A25-98DA-3DEA3668E2EBQ34129360-D15A6E5E-99CD-4850-AE25-66D1AA53DED5Q34441235-2B179BD2-9C72-4C97-B3A9-FF7BF41D8EC8Q34668891-8AEAF210-0DC5-4D7F-8C17-862B29E79C7CQ35083846-F87E53EC-6365-4862-8E1D-7255BB1DD7C8Q35184589-7DDED399-4D8D-41EA-84E9-09ABE750A81DQ35583502-30B601FD-83DB-4C07-BD25-78254504935EQ35918353-38BE8223-6DFA-4CA2-B321-F59DFAF5618EQ35972736-9D7DA0FE-4B8B-4422-AE31-8119CAF966F7Q35980234-41496163-1A0C-4907-9EF8-FC3ED17B821AQ36050572-4F7C729B-E217-4C13-8923-BEAC209CD237Q36054093-B7FAA30D-B878-4151-9F13-4A5649C3354FQ36341793-8139194E-95C1-418A-8F39-226ABD893A49Q36384673-A1492ECA-CFBE-4DE3-BF0C-52141BC6CEF3Q36652031-AA7B987D-FA05-4F57-845E-A5FDAA8B3F4DQ36711085-95931308-8772-4439-850E-B7BBCE470C58Q36765942-1D33CA78-FCE9-438D-B25A-28E92A4432BCQ36889289-74DB0841-8509-4664-8736-3F23B8240BDFQ36920414-E2C384D4-0EA2-4696-A6B9-FD6DC1DC1BF0Q36955927-14FEE0F2-2E79-4272-B25A-A1A1CECE3FADQ37178611-A023DA86-8C9E-4822-AF3B-F4E665494990Q37434315-B733AE3A-8B2C-4749-95B2-33E222405C45Q37539595-B5DCE772-D382-41A6-AD8B-353350D7EFBAQ38193165-F32C4AC1-030C-45BB-968C-184AB0BE4ACBQ38735119-0C93BDAF-F0C8-4C1F-9521-8FEE781AF17CQ39127814-16721494-8ADD-4F3A-B49E-4F8843986673Q42343473-8FF1CCE9-4071-4AD0-B212-6E1671151AA6Q43989398-2802AC0F-489D-48EF-825A-FF40252902B7Q44709602-99608419-D06A-4270-AA5A-110BF82F449CQ44860714-9CE5B277-5288-437F-9C37-0A468779EBD2Q45219593-572EEF7C-B71A-4FA5-B9A3-284127B4850BQ46401362-CFB2A907-8CB9-4009-AE17-358EB146632D
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Rapamycin: clinical results and future opportunities.
@ast
Rapamycin: clinical results and future opportunities.
@en
Rapamycin: clinical results and future opportunities.
@nl
type
label
Rapamycin: clinical results and future opportunities.
@ast
Rapamycin: clinical results and future opportunities.
@en
Rapamycin: clinical results and future opportunities.
@nl
prefLabel
Rapamycin: clinical results and future opportunities.
@ast
Rapamycin: clinical results and future opportunities.
@en
Rapamycin: clinical results and future opportunities.
@nl
P1433
P1476
Rapamycin: clinical results and future opportunities.
@en
P2093
P304
P356
10.1097/00007890-200110150-00001
P577
2001-10-01T00:00:00Z